Compare ANAB & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | DV |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2015 | 2021 |
| Metric | ANAB | DV |
|---|---|---|
| Price | $55.75 | $9.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $74.64 | $16.18 |
| AVG Volume (30 Days) | 587.2K | ★ 2.8M |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $234,603,000.00 | ★ $748,291,000.00 |
| Revenue This Year | N/A | $12.68 |
| Revenue Next Year | $33.49 | $9.75 |
| P/E Ratio | ★ N/A | $31.65 |
| Revenue Growth | ★ 157.01 | 13.92 |
| 52 Week Low | $15.40 | $7.61 |
| 52 Week High | $68.39 | $16.82 |
| Indicator | ANAB | DV |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 40.60 |
| Support Level | $52.68 | $8.95 |
| Resistance Level | $57.70 | $11.60 |
| Average True Range (ATR) | 4.06 | 0.35 |
| MACD | -1.35 | -0.08 |
| Stochastic Oscillator | 8.37 | 26.82 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.